Cogent Biosciences (COGT) Stock Price, News & Analysis

Company Overview

Cogent Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision medicines for genetically defined diseases. The company uses its research platform to discover and advance targeted therapies designed to address the underlying drivers of serious medical conditions.

Cogent’s lead product candidate is bezuclastinib, an oral, highly selective tyrosine kinase inhibitor designed to target the KIT D816V mutation and other KIT alterations. The company is developing bezuclastinib for systemic mastocytosis, a rare disorder involving the abnormal accumulation of mast cells, including both non-advanced and advanced forms of the disease.

Cogent Biosciences is headquartered in Boulder, Colorado, and conducts its clinical development activities through studies involving patients and research sites in multiple regions. The company is led by Andrew Robbins, who serves as president and chief executive officer.

Key Stats

• Today's Range: $30.35 to $31.95
• 50-Day Range: $31.41 to $42.84
• 52-Week Range: $12.97 to $43.73
• Volume: 2.05 million shs
• Average Volume: 2.17 million shs
• Market Capitalization: $5.44 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $51.56
• Consensus Rating: Moderate Buy

Cogent Biosciences Stock Analysis - MarketRank™

Cogent Biosciences scored higher than 40% of companies evaluated by MarketBeat, and ranked 633rd out of 901 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Cogent Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 1 strong buy rating, 8 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

Cogent Biosciences has a consensus price target of $51.56, representing about 64.5% upside from its current price of $31.35.

Amount of Analyst Coverage

Cogent Biosciences has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Cogent Biosciences are expected to grow in the coming year, from ($2.23) to ($1.27) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Cogent Biosciences is -14.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cogent Biosciences is -14.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Cogent Biosciences has a P/B Ratio of 8.16. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

11.57% of the float of Cogent Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Cogent Biosciences has a short interest ratio ("days to cover") of 12.09, which indicates bearish sentiment.

Change versus previous month

Short interest in Cogent Biosciences has recently increased by 1.83%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cogent Biosciences does not currently pay a dividend.

Dividend Growth

Cogent Biosciences does not have a long track record of dividend growth.

News and Social Media

• Score: 1.3 / 5
• News Sentiment: 0.15

News Sentiment

Cogent Biosciences has a news sentiment score of 0.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Cogent Biosciences this week, compared to 5 articles on an average week.

MarketBeat Follows

Only 1 people have added Cogent Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

Company Ownership

• Score: 0.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Cogent Biosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

6.59% of the stock of Cogent Biosciences is held by insiders.

Percentage Held by Institutions

Cogent Biosciences has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/10/2026
• Today: 9/24/2026
• Next Earnings (Estimated): 11/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:COGT
• CIK: 1622229
• Web: www.cogentbio.com
• Phone: (617) 945-5576
• Fax: N/A
• Employees: 258
• Year Founded: 2014

Price Target and Rating

• Average Price Target for Cogent Biosciences: $51.56
• High Price Target: $67.00
• Low Price Target: $35.00
• Potential Upside/Downside: +64.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 12 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.16)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$328.94 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -84.47%
• Return on Assets: -47.72%

Debt

• Debt-to-Equity Ratio: 0.48
• Current Ratio: 13.57
• Quick Ratio: 13.57

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.84 per share
• Price / Book: 8.16

Miscellaneous

• Outstanding Shares: 173,520,000
• Free Float: 162,090,000
• Market Cap: $5.44 billion
• Optionable: Optionable
• Beta: 0.31